8-K ·Filed May 5, 2026

SOLV

Solventum Corp
MIXED
Impact 6/10
Horizondays Processed4mo ago SEC0001964738-26-000022
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The adjusted EPS beat and maintained guidance with an upward bias on EPS provide a positive signal for underlying operations, but the deeply negative free cash flow and continued separation costs warrant caution. Monitor cash flow trajectory in Q2 and any updates on tariff impacts. The stock may see a modest positive reaction as the market focuses on adjusted metrics and organic growth.

DirectionMixed
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
SOLV ▲ +20.36% at T+60d
NEUTRAL call ✓ call won +20.36% · α vs SPY +18.29% · entry $70.99 → $85.44
Entry anchored
May 5, 03:59 PM ET
via exchange tick
T+1d
0.00%
call 0.00% · α +0.33%
$70.99
settled 5mo ago
T+5d
+5.79%
call +5.79% · α +4.66%
$75.10
settled 5mo ago
T+20d
+10.38%
call +10.38% · α +7.60%
$78.36
settled 4mo ago
T+60d
+20.36%
call +20.36% · α +18.29%
$85.44
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Solventum reported Q1 2026 adjusted EPS of $1.48, beating consensus of $1.35 by 9.6%, and affirmed full-year guidance with EPS expected toward the high end of $6.40-$6.60. However, reported revenue declined 3.0% YoY to $2.007B due to the divestiture of Purification and Filtration, while organic sales grew 2.1%. GAAP EPS collapsed to $0.07 from $0.78 due to separation and restructuring costs, and free cash flow was deeply negative at $(273)M, reflecting seasonal and transition outflows.

Key Financial Metrics

EPS
$1.48
est $1.35 · +9.6%
Revenue
$2.0B
-3.0% YoY
Rating
beat
Guidance
Organic +2.0% to +3.0%
affirmed
Free Cash Flow
-$273.0M
Gross Margin
54.6%

Key Facts

  • Q1 2026 net sales $2.007B, down 3.0% reported but up 2.1% organically
  • Adjusted diluted EPS $1.48, +10.6% YoY, vs consensus $1.35
  • GAAP diluted EPS $0.07, down 91% YoY due to separation/restructuring costs
  • FY2026 guidance affirmed: organic sales growth +2-3%, adjusted EPS toward high end of $6.40-$6.60, FCF $200M
  • Operating cash flow $(189)M, free cash flow $(273)M

Financial Impact

Adjusted EPS beat by 9.6% ($0.13); revenue $37M above Q4 2025 consensus but not comparable due to divestiture

epsrevenuecash flowmargins

Risk Factors

  • Negative free cash flow of $273M in Q1 due to separation activities and seasonality
  • Reported revenue declining 3% YoY, masking organic growth due to divestiture
  • Heavy restructuring and spin-off costs weighing on GAAP profitability
  • Tariff and inflation headwinds pressuring adjusted margins

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
52% bullish (21 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001964738-26-000022
Document: solv-20260505.htm0001964738-26-000022
Document: 0001964738-26-000022-index-headers.html0001964738-26-000022
Document: 0001964738-26-000022-index.html0001964738-26-000022
Document: 0001964738-26-000022.txt0001964738-26-000022
8-K Data (Synthetic)0001964738-26-000022
5 reports for SOLV
Performance horizon
Filters
Rows
Reports for SOLV — sortable, filterable
TypeNow
Aug 18, 2026
6w ago
3
NEUTRAL ★ 2/10
$87.81 $90.06▲ +2.56%▲ +4.08%$88.50 (+0.79%)
Jun 12, 2026
16w ago
Institutional Cluster
MIXED ★ 5/10
$78.87 $76.70▼ −2.75%▼ −4.53%$88.50 (+12.21%)
Jun 5, 2026
16w ago
8-K
NEUTRAL ★ 2/10
$78.76 $77.94▼ −1.04%▼ −2.67%$88.50 (+12.37%)
May 27, 2026
18w ago
8-K
NEUTRAL ★ 3/10
$75.94 $79.53▲ +4.73%▲ +7.87%$88.50 (+16.54%)
May 5, 2026
21w ago
8-K
MIXED ★ 6/10
$70.99 $78.36▲ +10.38%▲ +7.60%$88.50 (+24.67%)
Showing 5 of 5

US Market Status

Market Open — Closes in 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access